Analysts expect Emergent Biosolutions Inc (NYSE:EBS) to announce sales of $212.94 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Emergent Biosolutions’ earnings, with the lowest sales estimate coming in at $209.97 million and the highest estimate coming in at $215.90 million. Emergent Biosolutions reported sales of $220.20 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 3.3%. The business is expected to report its next earnings report on Thursday, August 1st.

On average, analysts expect that Emergent Biosolutions will report full year sales of $1.07 billion for the current financial year, with estimates ranging from $1.01 billion to $1.10 billion. For the next year, analysts expect that the company will report sales of $1.17 billion, with estimates ranging from $1.12 billion to $1.19 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.26). The company had revenue of $190.60 million during the quarter, compared to the consensus estimate of $201.36 million. Emergent Biosolutions had a net margin of 4.88% and a return on equity of 11.73%. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.03) earnings per share.

A number of equities analysts have issued reports on the company. Zacks Investment Research cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Monday, April 8th. Wells Fargo & Co set a $68.00 price objective on shares of Emergent Biosolutions and gave the company a “hold” rating in a research report on Tuesday, April 2nd. Cowen reaffirmed a “hold” rating and set a $60.00 target price on shares of Emergent Biosolutions in a research note on Friday, May 3rd. ValuEngine raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 target price on shares of Emergent Biosolutions in a research note on Sunday, April 21st. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Emergent Biosolutions currently has an average rating of “Buy” and an average price target of $68.86.

EBS traded down $0.10 during mid-day trading on Wednesday, reaching $44.29. The stock had a trading volume of 202,118 shares, compared to its average volume of 486,547. The stock has a fifty day moving average price of $44.83. The company has a quick ratio of 1.28, a current ratio of 2.13 and a debt-to-equity ratio of 0.74. The company has a market cap of $2.28 billion, a PE ratio of 19.01, a P/E/G ratio of 0.74 and a beta of 1.61. Emergent Biosolutions has a 52 week low of $39.64 and a 52 week high of $73.89.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,376 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $43.39, for a total transaction of $59,704.64. Following the sale, the director now owns 24,379 shares of the company’s stock, valued at $1,057,804.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 14.10% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. New York State Teachers Retirement System lifted its holdings in Emergent Biosolutions by 4.1% in the first quarter. New York State Teachers Retirement System now owns 43,313 shares of the biopharmaceutical company’s stock valued at $2,188,000 after buying an additional 1,710 shares during the period. Gideon Capital Advisors Inc. acquired a new position in Emergent Biosolutions in the fourth quarter valued at $570,000. Outlook Wealth Advisors LLC lifted its holdings in Emergent Biosolutions by 392.8% in the first quarter. Outlook Wealth Advisors LLC now owns 5,027 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 4,007 shares during the period. Comerica Bank lifted its holdings in Emergent Biosolutions by 3.9% in the first quarter. Comerica Bank now owns 68,018 shares of the biopharmaceutical company’s stock valued at $3,635,000 after buying an additional 2,524 shares during the period. Finally, Pitcairn Co. lifted its holdings in Emergent Biosolutions by 3.9% in the fourth quarter. Pitcairn Co. now owns 7,051 shares of the biopharmaceutical company’s stock valued at $418,000 after buying an additional 266 shares during the period. 86.42% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Read More: Why is a lock-up period needed for an IPO?

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.